Vivaldi Biosciences announced that the Flu Lab has provided a grant to fund a transmission study of the company’s DeltaFLU intranasal universal influenza vaccine. According to the company, the study will evaluate the ability of DeltaFlu to protect against transmission of “broadly divergent wild-type influenza type A and B strains” among ferrets.
The company noted that the National Institute of Allergy and Infectious Diseases (NIAID) and the European Union have provided funding for clinical trials of DeltaFLU in adult volunteers. In June 2023, the company reported that a €7.6 million grant from the EU to the FLUniversal consortium will fund a Phase 1 study of DeltaFLU.
Vivaldi is also developing an intranasal combined universal flu / SARs-CoV-2 vaccine called Delta-19.
Read the Vivaldi Biosciences press release.
